NCT06691256 · Phase 2 · ACTIVE NOT RECRUITING
Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation
This trial is testing a smart medication dispenser called HiDO-ALZ, designed for people living with both dementia and type 2 diabetes. The device uses facial recognition and video recording to confirm the right person takes the right medications at the right time, while sharing real-time data with caregivers and doctors. It is a Phase 2 trial, meaning researchers are expanding earlier work to test whether the device actually improves medication adherence at home.
You may qualify if
- Participants aged 65 or older.
- Diagnosed with both dementia and diabetes, with documented difficulty in maintaining at least one health marker (such as glucose, HbA1c, cholesterol, blood pressure, or weight) within target levels over the past 18-24 months.
- Mild cognitive impairment or early-stage dementia, as verified by a Montreal Cognitive Assessment (MoCA) score between 18 and 24.
You're excluded if
- Cognitive deficits or serious mental health or medical conditions that would compromise safety or the reliability of feedback.
- Contraindications to taking low-dose Vitamin C (100 mg).
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-01-30